These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 786108)

  • 1. Myasthenia gravis as a receptor disorder.
    Drachman DB; Kao I; Pestronk A; Toyka KV
    Ann N Y Acad Sci; 1976; 274():226-34. PubMed ID: 786108
    [No Abstract]   [Full Text] [Related]  

  • 2. Blockade of acetylcholine receptors: a model of myasthenia gravis.
    Satyamurti S; Drachman DB; Slone F
    Science; 1975 Mar; 187(4180):955-7. PubMed ID: 1145181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.
    Fambrough DM; Drachman DB; Satyamurti S
    Science; 1973 Oct; 182(4109):293-5. PubMed ID: 4742736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenia gravis animal model: quantitative analysis of the efficiency of pre- and postjunctional regions of intercostal muscles in rabbits immunized with Torpedo acetylcholine receptor.
    Albuquerque EX; Eldefrawi AT; Oliveira AC; Copio DS; Eldefrawi ME
    Exp Neurol; 1979 Oct; 66(1):109-22. PubMed ID: 225189
    [No Abstract]   [Full Text] [Related]  

  • 5. Characteristics and mechanism of neuromuscular block in myasthenia gravis.
    Grob D; Namba T
    Ann N Y Acad Sci; 1976; 274():143-73. PubMed ID: 183586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-immunogenic myasthenia gravis model and its application in a study of transsynaptic regulation at the neuromuscular junction.
    Molenaar PC; Oen BS; Plomp JJ; Van Kempen GT; Jennekens FG; Hesselmans LF
    Eur J Pharmacol; 1991 Apr; 196(1):93-101. PubMed ID: 1874282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some different aspects of post-tetanic phenomena in myasthenia gravis.
    Pinelli P; Arrigo A; Mille T
    Electroencephalogr Clin Neurophysiol; 1967 Aug; 23(2):190. PubMed ID: 4166736
    [No Abstract]   [Full Text] [Related]  

  • 8. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcholine receptors and end-plate electrophysiology in myasthenia gravis.
    Ito Y; Miledi R; Vincent A; Newsom-Davis J
    Brain; 1978 Jun; 101(2):345-68. PubMed ID: 667602
    [No Abstract]   [Full Text] [Related]  

  • 10. Acetylcholine receptor and myasthenia gravis.
    Fulpius BW; Zurn AD; Granato DA; Leder RM
    Ann N Y Acad Sci; 1976; 274():116-29. PubMed ID: 786106
    [No Abstract]   [Full Text] [Related]  

  • 11. An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis.
    Albuquerque EX; Rash JE; Mayer RF; Satterfield JR
    Exp Neurol; 1976 Jun; 51(3):536-63. PubMed ID: 179836
    [No Abstract]   [Full Text] [Related]  

  • 12. The kinetics of transmitter release in myasthenia gravis. I. An electrophysiological analysis of the storage of transmitter.
    Bergmans J; Rosselle N; Verheyen G; Schellens L
    Electromyogr Clin Neurophysiol; 1972; 12(5):443-88. PubMed ID: 4350884
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.
    Almon RR; Andrew CG; Appel SH
    Science; 1974 Oct; 186(4158):55-7. PubMed ID: 4421998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. End-plate potentials in experimental autoimmune myasthenia gravis in rats.
    Lambert EH; Lindstrom JM; Lennon VA
    Ann N Y Acad Sci; 1976; 274():300-18. PubMed ID: 1066990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases.
    Vincent A; Cull-Candy SG; Newsom-Davis J; Trautmann A; Molenaar PC; Polak RL
    Muscle Nerve; 1981; 4(4):306-18. PubMed ID: 7254233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic manipulation of AChR responses suggests multiple causes of weakness in slow-channel syndrome.
    Gomez CM; Maselli R; Williams JM; Bhattacharyya BB; Wollmann RL; Day JW
    Ann N Y Acad Sci; 1998 May; 841():167-80. PubMed ID: 9668235
    [No Abstract]   [Full Text] [Related]  

  • 17. Diffusion of acetylcholine in the synaptic cleft of normal and myasthenia gravis human endplates.
    Cull-Candy SG; Miledi R; Uchitel OD
    Nature; 1980 Jul; 286(5772):500-2. PubMed ID: 7402330
    [No Abstract]   [Full Text] [Related]  

  • 18. Acetylcholine release in diaphragm of rats with chronic experimental autoimmune myasthenia gravis.
    Kelly JJ; Lambert EH; Lennon VA
    Ann Neurol; 1978 Jul; 4(1):67-72. PubMed ID: 211931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of normal and myasthenic serum factors on innervated and chronically denervated mammalian muscles.
    Albuquerque EX; Lebeda FJ; Appel SH; Almon R; Kauffman FC; Mayer RF; Narahashi T; Yeh JZ
    Ann N Y Acad Sci; 1976; 274():475-92. PubMed ID: 1066995
    [No Abstract]   [Full Text] [Related]  

  • 20. Acetylcholine-induced channels and transmitter release at human endplates.
    Cull-Candy SG; Miledi R; Trautmann A
    Nature; 1978 Jan; 271(5640):74-5. PubMed ID: 625328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.